Sun Pharma Advanced Research Company
NSE: SPARC · ISIN INE232I01014 · Healthcare
₹210.90+13.87 (+7.04%)
Monday 9 November, 12:18 IST. Delayed. Source: Yahoo Finance.
Price chart
₹210.90 +13.87 (+7.04%) today
The day
- Previous close
- ₹197.03
- Open
- ₹199.00
- Day high
- ₹219.49
- Day low
- ₹196.50
Listed on NSE since 18 July 2007.
Key numbers
- Market value
- ₹6,844.16 Cr
- P/E (trailing)
- 4.26
- EPS (trailing)
- ₹49.50
- Price to book
- 4.76
- Dividend yield
- 0.00%
- Return on equity
- 298.1%
- Debt to equity
- 0.00
- Profit margin
- 84.7%
- Beta
- 0.67
- Volume today
- 2.39 Cr
- Average volume
- 9.15 L
Source: Yahoo Finance. Ratios use the latest reported (trailing twelve-month) figures.
Revenue and profit
| Year | Revenue | Net profit |
|---|---|---|
| FY23 | ₹238.78 Cr | ₹-222.58 Cr |
| FY24 | ₹75.55 Cr | ₹-387.21 Cr |
| FY25 | ₹71.77 Cr | ₹-342.51 Cr |
| FY26 | ₹39.15 Cr | ₹1,553.20 Cr |
Source: Yahoo Finance, from annual reports. Consolidated where reported.
Quarterly results
| Quarter | Revenue | Net profit | Profit vs year ago |
|---|---|---|---|
| Q2 FY27Jul–Sep 2026 | ₹30 Cr | ₹-26 Cr | – |
| Q1 FY27Apr–Jun 2026 | ₹40 Cr | ₹-21 Cr | – |
| Q4 FY26Jan–Mar 2026Audited | ₹1,853 Cr | ₹1,763 Cr | – |
| Q3 FY26Oct–Dec 2025 | ₹8 Cr | ₹-80 Cr | – |
| Q2 FY26Jul–Sep 2025 | ₹8 Cr | ₹-76 Cr | – |
| Q1 FY26Apr–Jun 2025 | ₹10 Cr | ₹-52 Cr | – |
Source: Sun Pharma Advanced Research Company’s results filed with NSE, consolidated (the whole group). Net profit is the share of Sun Pharma Advanced Research Company’s own shareholders where the filing separates it. Profit vs year ago compares with the same quarter a year earlier; – where that quarter is not on file or made a loss.
Download results (zip) A spreadsheet of the quarterly results and balance sheets, with the original filings from NSE.
Balance sheet
| As on | September 2026 | March 2026 |
|---|---|---|
| Fixed assets | ₹84 Cr | ₹86 Cr |
| Investments | ₹239 Cr | ₹0 |
| Owed by customers | ₹21 Cr | ₹8 Cr |
| Cash and equivalents | ₹3 Cr | ₹1 Cr |
| Total assets | ₹1,674 Cr | ₹2,171 Cr |
| Borrowings | ₹0 | ₹556 Cr |
| Total liabilities | ₹231 Cr | ₹832 Cr |
| Shareholders’ equity | ₹1,442 Cr | ₹1,339 Cr |
Source: Sun Pharma Advanced Research Company’s half-yearly statements of assets and liabilities filed with NSE, consolidated. Companies file these every September and March.
About Sun Pharma Advanced Research Company
Sun Pharma Advanced Research Company Limited engages in the research and development of pharmaceutical products in India and internationally. It develops Sezaby, a benzyl alcohol and propylene glycol free formulation of phenobarbital sodium injection for the treatment of neonatal seizures; SPARC-121, a novel topical agent for the treatment of Alopecia Areata; and SPARC-122, an anti-MUC1 ADC for treatment of multiple cancer indications. The company is also involved in the development of PDP-716 for treatment of open-angle glaucoma. Sun Pharma Advanced Research Company Limited was incorporated in 2006 and is based in Mumbai, India.
- Industry
- Drug Manufacturers - Specialty & Generic
- Based in
- Mumbai
- Employees
- 279
Company website · Profile: Yahoo Finance
In the news
All newsSun Pharma Share Price Live Updates: Sun Pharma's Current Market Price
The Economic Times · 9 Nov, 08:28
Mahurat Trading 2026 Highlights: Nifty closes below 25,000; Sun Pharma, Tata Steel, ONGC top gainers
CNBC-TV18 · 8 Nov, 15:42
Muhurat trading: Sensex up 320 pts, Nifty crosses 25,100; Tata Steel, Sun Pharma among top gainers
The Economic Times · 8 Nov, 15:05
Muhurat Trading Close: Sensex dips 29 pts, Nifty ends at 24,986; Sun Pharma, Tata Steel shine
Business Standard · 8 Nov, 13:32
Dividends and corporate actions
All companies- Annual General Meeting
Action · ex-date 21 September 2021
- Annual General Meeting
Action · ex-date 22 September 2020
- Annual General Meeting
Action · ex-date 18 July 2019
- Annual General Meeting
Action · ex-date 19 July 2018
- Annual General Meeting
Action · ex-date 27 July 2017
- Extraordinary General Meeting
Action · ex-date 25 May 2017
- Annual General Meeting
Action · ex-date 21 July 2016
- Rights 5: 116 At Premium Rs 244/- Per Share
Right · ex-date 16 March 2016 · record date 17 March 2016
Source: NSE. Latest first, 8 of 17.
Information only, not investment advice. Prices are delayed.